# US 2025/0017919 A1 · Method for treating cancer using a bcl-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeutic

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0017919 A1
- Document ID: US20250017919A1
- Status: Published application
- Kind: A1
- Application number: 18/901,169
- Filed: 2024-09-30
- Published: 2025-01-16
- Earliest claimed: 2017-04-28
- Assignees: Actinium Pharmaceuticals, Inc.
- Applicants: Actinium Pharmaceuticals, Inc.
- Inventors: Dragan Cicic
- Web page: https://patentgrep.com/patent/US20250017919A1

## CPC

- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61P 35/00: Antineoplastic agents
- A61K 31/635: having a heterocyclic ring, e.g. sulfadiazine
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 51/1027: {against receptors, cell-surface antigens or cell-surface determinants}
- A61K 51/1069: {the tumor cell being from blood cells, e.g. the cancer being a myeloma}
- A61K 51/1093: {conjugates with carriers being antibodies}
- A61K 51/1096: {radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications}
- A61P 35/02: specific for leukemia
- C07K 16/2803: {against the immunoglobulin superfamily}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

This invention provides a method for treating a subject afflicted with cancer, comprising administering to the subject (i) a BCL-2 inhibitor in conjunction with (ii) an alpha-emitting isotope-labeled agent that targets cancer cells in the subject, wherein the amounts of the BCL-2 inhibitor and labeled agent, when administered in conjunction with one another, are therapeutically effective. This invention also provides a method for inducing the death of a cancer cell, comprising contacting the cell with (i) a BCL-2 inhibitor in conjunction with (ii) an alpha-emitting isotope-labeled agent that targets the cancer cell, wherein the amounts of BCL-2 inhibitor and labeled agent, when concurrently contacted with the cell, are effective to induce the cell's death.

## Claims

### Claim 1

A method for treating a human subject afflicted with a hematological malignancy selected from myelodysplastic syndrome and a myeloproliferative disorder consisting of combination pharmaceutical therapy, wherein the combination pharmaceutical therapy comprises:
administering a BCL-2 inhibitor to the subject; in conjunction with
administering 225Ac-labeled HuM195 to the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the hematological malignancy is myelodysplastic syndrome.

### Claim 3 (depends on 1)

The method of claim 1, wherein the hematological malignancy is a myeloproliferative disorder selected from polycythemia vera, essential thrombocytosis, primary myelofibrosis and chronic myeloid leukemia.

### Claim 4 (depends on 3)

The method of claim 3, wherein the myeloproliferative disorder is polycythemia vera.

### Claim 5 (depends on 3)

The method of claim 3, wherein the myeloproliferative disorder is essential thrombocytosis.

### Claim 6 (depends on 3)

The method of claim 3, wherein the myeloproliferative disorder is primary myelofibrosis.

### Claim 7 (depends on 3)

The method of claim 3, wherein the myeloproliferative disorder is chronic myeloid leukemia.
